• Organogenesis won FDA filing acceptance for its Biologics License Application for ReNu to treat pain in symptomatic knee osteoarthritis.
• The FDA set a PDUFA target action date of April 24, 2027.
• The agency conditionally accepted Amnuvx (azimplacel) as the proposed proprietary name, pending final review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organogenesis Holdings Inc. published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.